| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Hans-Joachim Anders | |
| Matthias Schneider | |||
| Annegret Kuhn | |||
| Klaus Tenbrock | |||
| Gisela Bonsmann | |||
| Peter Herzer | |||
| P2860 | cites work | Treatment for lupus nephritis | Q24202572 |
| Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects | Q27023280 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Prognostic factors in systemic lupus erythematosus | Q33286668 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort | Q33455990 | ||
| Retinal toxicity in long term hydroxychloroquine treatment | Q33578793 | ||
| Drug-induced lupus: an update | Q34127733 | ||
| EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs | Q34132211 | ||
| Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 | ||
| European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies | Q34187282 | ||
| The classification of glomerulonephritis in systemic lupus erythematosus revisited | Q34293066 | ||
| The relation between sun protection factor and amount of suncreen applied in vivo | Q34627062 | ||
| Can morbidity and mortality of SLE be improved? | Q34664126 | ||
| Update on systemic lupus erythematosus pregnancy | Q35756117 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Topical calcineurin inhibitors in cutaneous lupus erythematosus | Q37271733 | ||
| The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus | Q37591255 | ||
| Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus | Q37756231 | ||
| Cutaneous lupus erythematosus: Update of therapeutic options | Q37782472 | ||
| EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases | Q37816066 | ||
| Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus | Q37902377 | ||
| An update on childhood-onset systemic lupus erythematosus | Q38120191 | ||
| Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies | Q38149856 | ||
| Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis | Q38173894 | ||
| Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy | Q38176594 | ||
| Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. | Q39176027 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study | Q41192552 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| Use of antimalarials in dermatology | Q41935321 | ||
| Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking | Q41938899 | ||
| Antimalarials. A treatment option for every lupus patient!? | Q41939554 | ||
| Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival | Q41941085 | ||
| Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis | Q41944990 | ||
| Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus | Q41977234 | ||
| Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial | Q43205821 | ||
| A surge in anti-dsDNA titer predicts a severe lupus flare within six months | Q43677777 | ||
| Statement on the use of mycophenolate mofetil for systemic lupus erythematosus | Q44108515 | ||
| Early lupus erythematosus | Q45081541 | ||
| Recommendation for use of belimumab for systemic lupus erythematosus | Q45122982 | ||
| The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine | Q46158721 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. | Q50669021 | ||
| Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. | Q51056997 | ||
| Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. | Q51150943 | ||
| Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. | Q51474220 | ||
| Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. | Q54140008 | ||
| Revised Cutaneous Lupus erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus | Q60048342 | ||
| Distinctive cutaneous subsets in the spectrum of lupus erythematosus | Q70765321 | ||
| Evolving spectrum of mortality and morbidity in SLE | Q78020618 | ||
| Antimalarial agents: closing the gate on Toll-like receptors? | Q79158393 | ||
| [Laboratory diagnostics of systemic autoimmune diseases. Part 1. Collagenoses] | Q79375343 | ||
| Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis | Q79869714 | ||
| [EULAR recommendations for the management of systemic lupus erythematosus] | Q83863912 | ||
| [Skin manifestations in lupus erythematosus: clinical aspects and therapy] | Q83869346 | ||
| [Rheumatic diseases during pregnancy] | Q84371939 | ||
| [Systemic lupus erythematosus. A problem based approach] | Q84566584 | ||
| [Changes in mortality and morbidity in systemic lupus erythematosus] | Q84815168 | ||
| [Systemic lupus erythematosus] | Q94461762 | ||
| P433 | issue | 25 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 423-432 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Deutsches Ärzteblatt international | Q27722165 |
| P1476 | title | The Diagnosis and Treatment of Systemic Lupus Erythematosus | |
| P478 | volume | 112 |
| Q92106947 | A General Introduction to Glucocorticoid Biology |
| Q60948706 | Awareness of Systemic Lupus Erythematosus among Primary Health Care Patients in Riyadh, Saudi Arabia |
| Q36898946 | Budd- Chiari Syndrome as an Initial Manifestation of Systemic Lupus Erythematosus. |
| Q90403019 | Cardiac Tamponade in an 18-year-old Male with Undiagnosed Systemic Lupus Erythematosus |
| Q62813916 | Cohort profile: The LoewenKIDS Study – life-course perspective on infections, the microbiome and the development of the immune system in early childhood |
| Q64076124 | Coordinated Induction of Antimicrobial Response Factors in Systemic Lupus Erythematosus |
| Q51147794 | Detection of epitopes in systemic lupus erythematosus using peptide microarray. |
| Q89450623 | Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis |
| Q90589213 | Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders |
| Q48275541 | Frequency and Type of Hepatic and Gastrointestinal Involvement in Juvenile Systemic Lupus Erythematosus |
| Q38659241 | Lupus erythematosus revisited. |
| Q58616776 | PD-1 immunobiology in systemic lupus erythematosus |
| Q40496217 | Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus |
| Q59808159 | Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort |
| Q31047067 | Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy |
| Q93271975 | Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA |
| Q45376906 | Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array |
| Q57460208 | Systemic lupus erythematosus and antineutrophilic cytoplasmic antibody-associated vasculitis overlap syndrome complicated by subarachnoid hemorrhage: case-based review |
| Q64884831 | The development of an end-to-end service solution to support lupus patients and improve their experience in clinical trials. |
| Q98947637 | The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach |
| Q89030349 | [Connective tissue diseases in adolescents] |
| Q54454444 | [Effect of allergic rhinitis on disease condition and treatment in patients with juvenile-onset systemic lupus erythematosus]. |
| Q86879317 | [Molecular diagnosis of collagen vascular diseases and vasculitides] |
Search more.